Home / Indication Insights / Epidemiology Insights / Graft versus host disease (GVHD)- Epidemiology Forecast to 2023
Graft versus host disease (GVHD)- Epidemiology Forecast to 2023
Date: Dec, 2017
Type: Pharmaceutical Industry Report
Pages: 40
Geography: Global
Delivery Timeline: 48 hrs
SKU: DIEI0006
DelveInsight's "Graft Versus Host Disease (GVHD) -Epidemiology Insights -2023" Report provides an overview of the disease GVHD for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs) from 2013-2023.
GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD happens when particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them. The disease is divided into two sub-types, acute GVHD which occurs usually in the initial 2-3 months after transplantation, and chronic GVHD that occurs after 3-4 months after transplantation and has more diverse complications. Although being used as a preventive therapy rather than treatment, Temcell-HS is currently the only therapy available for GVHD. It is marketed in Canada, Japan and Netherlands. According to DelveInsight, the total number of HSCTs and number of incident cases for first HSCTs is expected to grow at a CAGR of 2.80% and 2.90% respectively for the period 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- The Report covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD happens when particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them. The disease is divided into two sub-types, acute GVHD which occurs usually in the initial 2-3 months after transplantation, and chronic GVHD that occurs after 3-4 months after transplantation and has more diverse complications. Although being used as a preventive therapy rather than treatment, Temcell-HS is currently the only therapy available for GVHD. It is marketed in Canada, Japan and Netherlands. According to DelveInsight, the total number of HSCTs and number of incident cases for first HSCTs is expected to grow at a CAGR of 2.80% and 2.90% respectively for the period 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- The Report covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
1. Graft Versus Host Disease (GVHD) Overview
• Disease Definition
• Disease Types
• Acute GvHD
• Chronic GvHD
• Grades of GvHD
• Pathophysiology
• Risk Factors for GVHD
• Diagnosis
2. Epidemiology and Patient Population
• Key Points
3. UNITED STATES
• Assumptions and Rationale
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States
4. EUROPE
• Assumptions and Rationale
4.1 Germany
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany
4.2 France
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France
4.3 Spain
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain
4.4 Italy
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy
4.5 United Kingdom
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK
5. JAPAN
• Assumptions and Rationale
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
6. Appendix
7. Report Methodology
8. Consulting Services
9. Disclaimer
10. About DelveInsight
• Disease Definition
• Disease Types
• Acute GvHD
• Chronic GvHD
• Grades of GvHD
• Pathophysiology
• Risk Factors for GVHD
• Diagnosis
2. Epidemiology and Patient Population
• Key Points
3. UNITED STATES
• Assumptions and Rationale
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States
4. EUROPE
• Assumptions and Rationale
4.1 Germany
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany
4.2 France
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France
4.3 Spain
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain
4.4 Italy
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy
4.5 United Kingdom
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK
5. JAPAN
• Assumptions and Rationale
• Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan
• Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
• Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
6. Appendix
7. Report Methodology
8. Consulting Services
9. Disclaimer
10. About DelveInsight
Table 1: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2013-2023)
Table 2: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Table 3: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Table 4: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2013-2023)
Table 5: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Table 6: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Table 7: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2013-2023)
Table 8: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Table 9: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Table 10: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2013-2023)
Table 11: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Table 12: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Table 13: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2013-2023)
Table 14: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Table 15: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Table 16: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2013-2023)
Table 17: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Table 18: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Table 19: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2013-2023)
Table 20: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Table 21: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Table 2: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Table 3: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Table 4: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2013-2023)
Table 5: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Table 6: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Table 7: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2013-2023)
Table 8: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Table 9: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Table 10: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2013-2023)
Table 11: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Table 12: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Table 13: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2013-2023)
Table 14: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Table 15: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Table 16: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2013-2023)
Table 17: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Table 18: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Table 19: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2013-2023)
Table 20: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Table 21: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Figure 1: Pathophysiology of GvHD
Figure 2: Risk Factors for GvHD
Figure 3: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2013-2023)
Figure 4: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Figure 5: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Figure 6: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2013-2023)
Figure 7: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Figure 8: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Figure 9: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2013-2023)
Figure 10: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Figure 11: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Figure 12: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2013-2023)
Figure 13: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Figure 14: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Figure 15: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2013-2023)
Figure 16: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Figure 17: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Figure 18: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2013-2023)
Figure 19: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Figure 20: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Figure 21: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2013-2023)
Figure 22: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Figure 23: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Figure 2: Risk Factors for GvHD
Figure 3: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2013-2023)
Figure 4: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Figure 5: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Figure 6: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2013-2023)
Figure 7: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Figure 8: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Figure 9: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2013-2023)
Figure 10: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Figure 11: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Figure 12: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2013-2023)
Figure 13: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Figure 14: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Figure 15: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2013-2023)
Figure 16: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Figure 17: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Figure 18: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2013-2023)
Figure 19: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Figure 20: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Figure 21: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2013-2023)
Figure 22: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Figure 23: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Graft versus host disease (GVHD) Disease Overview
Graft versus host disease (GVHD) Prevalence
Graft versus host disease (GVHD) Incidence
Graft versus host disease (GVHD) Risk Factors
Graft versus host disease (GVHD) Epidemiology
Graft versus host disease (GVHD) Patient Populations
Graft versus host disease (GVHD) Diagnosed Patients
Graft versus host disease (GVHD) Forecast
Graft versus host disease (GVHD) Epidemiology Forecast
Graft versus host disease (GVHD) Treated patients/population
